Y Intercept Hong Kong Ltd Buys 38,809 Shares of ADMA Biologics Inc $ADMA

Y Intercept Hong Kong Ltd boosted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 107.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 74,891 shares of the biotechnology company’s stock after purchasing an additional 38,809 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in ADMA Biologics were worth $1,364,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Invesco Ltd. boosted its position in ADMA Biologics by 13.9% during the first quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company’s stock worth $255,279,000 after purchasing an additional 1,570,649 shares during the period. Nuveen LLC acquired a new position in shares of ADMA Biologics during the first quarter worth approximately $93,543,000. American Century Companies Inc. lifted its holdings in shares of ADMA Biologics by 12.7% during the first quarter. American Century Companies Inc. now owns 4,252,362 shares of the biotechnology company’s stock worth $84,367,000 after buying an additional 478,800 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of ADMA Biologics by 8.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 3,320,251 shares of the biotechnology company’s stock worth $59,366,000 after buying an additional 271,305 shares during the last quarter. Finally, Driehaus Capital Management LLC lifted its holdings in shares of ADMA Biologics by 114.9% during the first quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company’s stock worth $58,460,000 after buying an additional 1,575,363 shares during the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA opened at $15.48 on Monday. The business has a fifty day simple moving average of $15.61 and a 200 day simple moving average of $18.06. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $3.69 billion, a price-to-earnings ratio of 18.00 and a beta of 0.47. ADMA Biologics Inc has a one year low of $13.50 and a one year high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. The business had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.ADMA Biologics’s revenue was up 13.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.13 earnings per share. Sell-side analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 24th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $27.67.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.